Another strategy is the administration of interleukin-37 (IL-37), a member of IL-1 family [139], which is able to reduce the MyD88/NLRP3-IL-1/IL-6 pathway [140], ameliorating pneumonia [141], viral myocarditis [142] (through Th17/regulatory T cell immune response), and other infectious diseases. Here, IL37 is linked to infectious disease.